Articles and Insights About Wearables for Clinical Trials

We are excited to announce our participation in DiMe's Physical Activity, the latest digital clinical measures project. In partnership with the Digital Medicine Society (DiMe) and other leaders in the field, we are developing a core set of digital measures for tracking patients’ physical activity across any therapeutic area.

Clinicians, researchers, and drug developers need to have a shared baseline of digital measures to improve our patients’ health, regardless of their disease or condition. By taking an omni-therapeutic approach, we believe we can reduce time and risk, speeding the development of new therapies to market. Read more about the project.

Vivosense is pleased to announce that Ieuan Clay has joined the company as Director of Science. He brings extensive knowledge in developing and validating novel digital measures gained across experiences in industry, healthtech and academia.

VivoSense, an agile end-to-end digital clinical endpoint solutions company developing digital endpoints from wearable sensors with their proprietary AI-enabled software platform is proud to join an alliance of over one hundred and twenty life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA), is uniting industry stakeholders, including healthcare companies, regulators, patient groups, research organizations and technology providers with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

SAS Principal Industry Consultant Stijn Rogiers interviewed VivoSense CEO Dudley Tabakin about the uptake in decentralized clinical trials in response to the ongoing disruptions caused by the Coronavirus pandemic of 2020. As trials move toward decentralization, new processes and strategies are required to effectively collect and analyze patient data in a meaningful and validated way. Here are a few key takeaways from their conversation.

Pharmaphorum interviewed VivoSense Chief Product Officer and co-founder Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.

Vivosense is pleased to announce that Rob Wilson has joined the company as VP of Marketing Strategy. He brings more than 30 years of expertise in strategic planning, finance, and business development for a wide range of companies in digital health, biotechnology, medical technology, and healthcare service industries.

Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers.

Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund.

NEWPORT BEACH, Calif. – March 30, 2022-- VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, today announced the close of a $25 Million Series A financing round. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

VivoSense, Inc. is proud to announce that we have been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care.

Image Source: RSRT, Randol Family

VivoSense announces a series of new collaborations with the Rett Syndrome Research Trust (RSRT) to develop digital biomarkers that better assess the symptoms of Rett syndrome, focusing on autonomic dysfunction and other difficult-to-evaluate symptoms. The goal in developing these digital biomarkers is to better quantify and understand symptom impact on everyday life and to assess new treatments accurately.

ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will enhance the ability of both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.